Paeds · endocrinology-diabetes-and-growth
Type 1 diabetes: insulin therapy, technology and ambulatory care
Also known as Insulin therapy in type 1 diabetes · Basal-bolus regimen · Multiple daily injections · Insulin pump therapy · Continuous subcutaneous insulin infusion · Continuous glucose monitoring · Hybrid closed-loop · Automated insulin delivery · Diabetes ambulatory care · Sick-day management
Fellowship guide to ongoing insulin therapy, diabetes technology and ambulatory care in children and adolescents with type 1 diabetes: the insulin pharmacology that drives regimen choice, the basal-bolus and pump pathways, continuous glucose monitoring and hybrid closed-loop systems, sick-day and exercise rules, hypoglycaemia prevention, school care plans, HbA1c targets, and structured transition to adult care.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Insulin must never be stopped during an intercurrent illness — the dose is adjusted up for fever and hyperglycaemia, and stopping it is the fastest route to diabetic ketoacidosis
- A child with vomiting and blood ketones above 1.5 millimoles per litre on sick-day management is heading for ketoacidosis and needs escalation, not more fluids at home
- Recurrent severe hypoglycaemia in a child on a pump usually means a blocked cannula or site failure rather than overtreatment — check the infusion set before adjusting the algorithm
- Disordered eating and insulin omission for weight control are common in adolescent girls and present as unexpectedly high HbA1c with frequent ketones — screen actively and non-judgementally
- A pump user can develop ketoacidosis within hours of a cannula failure because there is no long-acting basal depot — always check ketones in any unwell pump-treated child
- Loss of hypoglycaemia awareness predicts the next severe episode — tighten targets only after awareness is restored, and consider technology that predicts lows
Life stages
Care settings
Clinical exam formats
Board mappings
- Insulin therapy and diabetes technology in type 1 diabetes
- Insulin therapy, pump and closed-loop management
- Insulin regimens, continuous glucose monitoring and closed-loop systems
- Long case: ambulatory type 1 diabetes and technology
- Diabetes mellitus: ongoing management and technology
- Insulin therapy and diabetes technology
- Diabetes: ambulatory and sick-day management
- Type 1 diabetes mellitus: management and technology
- Patient Care: insulin therapy, technology and ambulatory diabetes care
- Medical Expert: type 1 diabetes ambulatory management
This page covers the ongoing care of children and adolescents with established type 1 diabetes: the insulin pharmacology that decides the regimen, the basal-bolus and pump pathways, continuous glucose monitoring and hybrid closed-loop systems, and the ambulatory framework of sick-day rules, exercise planning, hypoglycaemia prevention, school care and transition. It assumes the diagnosis has been made and the first days managed on the dedicated diagnosis leaf, and it links to the diabetic ketoacidosis and hypoglycaemia leaves rather than repeating their protocols. [1] [12]
Overview & Definition
Type 1 diabetes is a lifelong insulin-deficiency disease. Once the honeymoon fades, the child depends entirely on exogenous insulin to survive, and the work of ongoing care is to deliver that insulin in a way that holds glucose near normal without trading control for hypoglycaemia or quality of life. [1] [12]
The goal of therapy has shifted over a generation. Where the target was once to avoid ketoacidosis and gross symptoms, the modern aim is an HbA1c below 7 percent, a time-in-range above 70 percent, and the lowest possible burden of severe hypoglycaemia — all while the child grows, learns, plays and moves toward independence. Technology has made that aim reachable for more children, but it has not removed the need for disciplined daily decisions. [4]
References12ShowHide
- [1]Cengiz E; Danne T; et al ISPAD Clinical Practice Consensus Guidelines 2024: Insulin and adjunctive treatments in children and adolescents with diabetes. Horm Res Paediatr, 2024.PMID 39884261
- [2]Biester T; Berget C; et al ISPAD Clinical Practice Consensus Guidelines 2024: Diabetes technologies — insulin delivery. Horm Res Paediatr, 2024.PMID 39657603
- [3]Tauschmann M; Cardona-Hernandez R; et al ISPAD Clinical Practice Consensus Guidelines 2024: Diabetes technologies — glucose monitoring. Horm Res Paediatr, 2024.PMID 39884260
- [4]de Bock M; Agwu JC; et al ISPAD Clinical Practice Consensus Guidelines 2024: Glycemic targets. Horm Res Paediatr, 2024.PMID 39701064
- [5]Haller MJ; Bell KJ; et al ISPAD Clinical Practice Consensus Guidelines 2024: Screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr, 2024.PMID 39662065
- [6]Wadwa RP; Reed ZW; et al Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med, 2023.PMID 36920756
- [7]Battelino T; Kuusela S; et al Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial. Lancet Diabetes Endocrinol, 2025.PMID 40544853
- [8]Phelan H; Hanas R; et al Sick day management in children and adolescents with diabetes. Pediatr Diabetes, 2022.PMID 36093857
- [9]Zimmermann AT; Lanzinger S; et al Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries. Lancet Diabetes Endocrinol, 2025.PMID 39622257
- [10]Lawrence JM; Divers J; et al Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA, 2021.PMID 34427600
- [11]Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008.PMID 18779236
- [12]DiMeglio LA; Evans-Molina C; Oram RA Type 1 diabetes. Lancet, 2018.PMID 29916386